Status:
COMPLETED
Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
The present study has been designed to characterize IPF patients treated with nintedanib (OFEV®), at time of treatment initiation, with respect to their clinical profile based on real-world data from ...
Eligibility Criteria
Inclusion
- The patient is at least 18 years old
- The patient has IPF diagnosis according to most recent ATS/ERS/JRS/ALAT IPF guideline for diagnosis and management \[5\]
- The patient newly initiated treatment with nintedanib (OFEV®) since 01 January 2016 up to end of data collection date, according to the approved local Summary of Product Characteristics (SmPC)
Exclusion
- \- Patients treated with nintedanib within a clinical trial or named-patient program or with any prior treatment of nintedanib.
Key Trial Info
Start Date :
October 24 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 7 2018
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT03281200
Start Date
October 24 2017
End Date
June 7 2018
Last Update
August 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dynamic solutions
Barcelona, Spain, 08029